{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T02:09:14Z","timestamp":1791425354362,"version":"4.3.3"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2014,6,27]],"date-time":"2014-06-27T00:00:00Z","timestamp":1403827200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/2.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Cancer"],"published-print":{"date-parts":[[2014,12]]},"DOI":"10.1186\/1476-4598-13-159","type":"journal-article","created":{"date-parts":[[2014,6,27]],"date-time":"2014-06-27T17:02:49Z","timestamp":1403888569000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":41,"title":["Downregulation of deoxycytidine kinase in cytarabine-resistant mantle cell lymphoma cells confers cross-resistance to nucleoside analogs gemcitabine, fludarabine and cladribine, but not to other classes of anti-lymphoma agents"],"prefix":"10.1186","volume":"13","author":[{"given":"Magdalena","family":"Klanova","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucie","family":"Lorkova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ondrej","family":"Vit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bokang","family":"Maswabi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Molinsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jana","family":"Pospisilova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petra","family":"Vockova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cory","family":"Mavis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucie","family":"Lateckova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vojtech","family":"Kulvait","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dana","family":"Vejmelkova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Radek","family":"Jaksa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisco","family":"Hernandez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marek","family":"Trneny","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Vokurka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiri","family":"Petrak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr","given":"Pavel","family":"Klener","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2014,6,27]]},"reference":[{"key":"1366_CR1","doi-asserted-by":"publisher","first-page":"699","DOI":"10.3109\/10428194.2012.733882","volume":"54","author":"M Dreyling","year":"2013","unstructured":"Dreyling M, Kluin-Nelemans HC, Be\u00e0 S, Klapper W, Vogt N, Delfau-Larue M-H, Hutter G, Cheah C, Chiappella A, Cortelazzo S, Pott C, Hess G, Visco C, Vitolo U, Klener P, Aurer I, Unterhalt M, Ribrag V, Hoster E, Hermine O: Update on the molecular pathogenesis and clinical treatment of mantle cell lymphoma: report of the 11th annual conference of the European Mantle Cell Lymphoma Network. Leuk Lymphoma. 2013, 54: 699-707.","journal-title":"Leuk Lymphoma"},{"key":"1366_CR2","doi-asserted-by":"publisher","first-page":"3416","DOI":"10.1172\/JCI61272","volume":"122","author":"P Jares","year":"2012","unstructured":"Jares P, Colomer D, Campo E: Molecular pathogenesis of mantle cell lymphoma. J Clin Invest. 2012, 122: 3416-3423.","journal-title":"J Clin Invest"},{"key":"1366_CR3","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1182\/blood-2011-09-370320","volume":"121","author":"R Delarue","year":"2013","unstructured":"Delarue R, Haioun C, Ribrag V, Brice P, Delmer A, Tilly H, Salles G, Van Hoof A, Casasnovas O, Brousse N, Lefrere F, Hermine O: CHOP and DHAP plus rituximab followed by autologous stem cell transplantation in mantle cell lymphoma: a phase 2 study from the Groupe d\u2019Etude des Lymphomes de l\u2019Adulte. Blood. 2013, 121: 48-53.","journal-title":"Blood"},{"key":"1366_CR4","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1038\/sj.leu.2402406","volume":"16","author":"F Lefr\u00e8re","year":"2002","unstructured":"Lefr\u00e8re F, Delmer A, Suzan F, Levy V, Belanger C, Djabarri M, Arnulf B, Damaj G, Maillard N, Ribrag V, Janvier M, Sebban C, Casasnovas R-O, Bouabdallah R, Dreyfus F, Verkarre V, Delabesse E, Valensi F, McIntyre E, Brousse N, Varet B, Hermine O: Sequential chemotherapy by CHOP and DHAP regimens followed by high-dose therapy with stem cell transplantation induces a high rate of complete response and improves event-free survival in mantle cell lymphoma: a prospective study. Leukemia. 2002, 16: 587-593.","journal-title":"Leukemia"},{"key":"1366_CR5","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1111\/j.1365-2141.2011.08958.x","volume":"156","author":"F Merli","year":"2012","unstructured":"Merli F, Luminari S, Ilariucci F, Petrini M, Visco C, Ambrosetti A, Stelitano C, Caracciolo F, Di Renzo N, Angrilli F, Carella AM, Capodanno I, Barbolini E, Galimberti S, Federico M: Rituximab plus HyperCVAD alternating with high dose cytarabine and methotrexate for the initial treatment of patients with mantle cell lymphoma, a multicentre trial from Gruppo Italiano Studio Linfomi. Br J Haematol. 2012, 156: 346-353.","journal-title":"Br J Haematol"},{"key":"1366_CR6","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1097\/CCO.0b013e328363df0b","volume":"25","author":"S Ferrero","year":"2013","unstructured":"Ferrero S, Dreyling M: The current therapeutic scenario for relapsed mantle cell lymphoma. Curr Opin Oncol. 2013, 25: 452-462.","journal-title":"Curr Opin Oncol"},{"key":"1366_CR7","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1056\/NEJMoa1306220","volume":"369","author":"ML Wang","year":"2013","unstructured":"Wang ML, Rule S, Martin P, Goy A, Auer R, Kahl BS, Jurczak W, Advani RH, Romaguera JE, Williams ME, Barrientos JC, Chmielowska E, Radford J, Stilgenbauer S, Dreyling M, Jedrzejczak WW, Johnson P, Spurgeon SE, Li L, Zhang L, Newberry K, Ou Z, Cheng N, Fang B, McGreivy J, Clow F, Buggy JJ, Chang BY, Beaupre DM, Kunkel LA, Blum KA: Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. N Engl J Med. 2013, 369: 507-516.","journal-title":"N Engl J Med"},{"key":"1366_CR8","doi-asserted-by":"publisher","first-page":"3688","DOI":"10.1200\/JCO.2013.49.2835","volume":"31","author":"A Goy","year":"2013","unstructured":"Goy A, Sinha R, Williams ME, Kalayoglu Besisik S, Drach J, Ramchandren R, Zhang L, Cicero S, Fu T, Witzig TE: Single-agent lenalidomide in patients with mantle-cell lymphoma who relapsed or progressed after or were refractory to Bortezomib: phase II MCL-001 (EMERGE) study. J Clin Oncol. 2013, 31: 3688-3695.","journal-title":"J Clin Oncol"},{"key":"1366_CR9","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1200\/JCO.2005.03.108","volume":"23","author":"A Goy","year":"2005","unstructured":"Goy A, Younes A, McLaughlin P, Pro B, Romaguera JE, Hagemeister F, Fayad L, Dang NH, Samaniego F, Wang M, Broglio K, Samuels B, Gilles F, Sarris AH, Hart S, Trehu E, Schenkein D, Cabanillas F, Rodriguez AM: Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin\u2019s lymphoma. J Clin Oncol. 2005, 23: 667-675.","journal-title":"J Clin Oncol"},{"key":"1366_CR10","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1016\/S1470-2045(11)70062-6","volume":"12","author":"SM Ansell","year":"2011","unstructured":"Ansell SM, Tang H, Kurtin PJ, Koenig PA, Inwards DJ, Shah K, Ziesmer SC, Feldman AL, Rao R, Gupta M, Erlichman C, Witzig TE: Temsirolimus and rituximab in patients with relapsed or refractory mantle cell lymphoma: a phase 2 study. Lancet Oncol. 2011, 12: 361-368.","journal-title":"Lancet Oncol"},{"key":"1366_CR11","doi-asserted-by":"publisher","first-page":"5347","DOI":"10.1200\/JCO.2005.13.466","volume":"23","author":"TE Witzig","year":"2005","unstructured":"Witzig TE, Geyer SM, Ghobrial I, Inwards DJ, Fonseca R, Kurtin P, Ansell SM, Luyun R, Flynn PJ, Morton RF, Dakhil SR, Gross H, Kaufmann SH: Phase II trial of single-agent temsirolimus (CCI-779) for relapsed mantle cell lymphoma. J Clin Oncol. 2005, 23: 5347-5356.","journal-title":"J Clin Oncol"},{"key":"1366_CR12","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1002\/ajh.23176","volume":"87","author":"JM Vose","year":"2012","unstructured":"Vose JM: Mantle cell lymphoma: 2012 update on diagnosis, risk-stratification, and clinical management. Am J Hematol. 2012, 87: 604-609.","journal-title":"Am J Hematol"},{"key":"1366_CR13","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.1080\/10428190701361216","volume":"48","author":"T Robak","year":"2007","unstructured":"Robak T, Lech-Maranda E, Janus A, Blonski J, Wierzbowska A, Gora-Tybor J: Cladribine combined with cyclophosphamide and mitoxantrone is an active salvage therapy in advanced non-Hodgkin\u2019s lymphoma. Leuk Lymphoma. 2007, 48: 1092-1101.","journal-title":"Leuk Lymphoma"},{"key":"1366_CR14","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1093\/annonc\/mdl395","volume":"18","author":"F Morschhauser","year":"2007","unstructured":"Morschhauser F, Depil S, Jourdan E, Wetterwald M, Bouabdallah R, Marit G, Solal-C\u00e9ligny P, Sebban C, Coiffier B, Chouaki N, Bauters F, Dumontet C: Phase II study of gemcitabine-dexamethasone with or without cisplatin in relapsed or refractory mantle cell lymphoma. Ann Oncol. 2007, 18: 370-375.","journal-title":"Ann Oncol"},{"issue":"Suppl 1","key":"1366_CR15","doi-asserted-by":"publisher","first-page":"S50","DOI":"10.1038\/sj.thj.6200391","volume":"5","author":"SA Johnson","year":"2004","unstructured":"Johnson SA: Use of fludarabine in the treatment of mantle cell lymphoma, Waldenstr\u00f6m\u2019s macroglobulinemia and other uncommon B- and T-cell lymphoid malignancies. Hematol J. 2004, 5 (Suppl 1): S50-S61.","journal-title":"Hematol J"},{"key":"1366_CR16","doi-asserted-by":"publisher","first-page":"1442","DOI":"10.1200\/JCO.2012.45.9842","volume":"31","author":"C Visco","year":"2013","unstructured":"Visco C, Finotto S, Zambello R, Paolini R, Menin A, Zanotti R, Zaja F, Semenzato G, Pizzolo G, D\u2019Amore ESG, Rodeghiero F: Combination of rituximab, bendamustine, and cytarabine for patients with mantle-cell non-Hodgkin lymphoma ineligible for intensive regimens or autologous transplantation. J Clin Oncol. 2013, 31: 1442-1449.","journal-title":"J Clin Oncol"},{"key":"1366_CR17","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1182\/blood.V32.4.507.507","volume":"32","author":"RR Ellison","year":"1968","unstructured":"Ellison RR, Holland JF, Weil M, Jacquillat C, Boiron M, Bernard J, Sawitsky A, Rosner F, Gussoff B, Silver RT, Karanas A, Cuttner J, Spurr CL, Hayes DM, Blom J, Leone LA, Haurani F, Kyle R, Hutchison JL, Forcier RJ, Moon JH: Arabinosyl cytosine: a useful agent in the treatment of acute leukemia in adults. Blood. 1968, 32: 507-523.","journal-title":"Blood"},{"key":"1366_CR18","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1200\/JCO.1983.1.11.689","volume":"1","author":"H Kantarjian","year":"1983","unstructured":"Kantarjian H, Barlogie B, Plunkett W, Velasquez W, McLaughlin P, Riggs S, Cabanillas F: High-dose cytosine arabinoside in non-Hodgkin\u2019s lymphoma. J Clin Oncol. 1983, 1: 689-694.","journal-title":"J Clin Oncol"},{"key":"1366_CR19","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1007\/BF00194527","volume":"14","author":"RL Capizzi","year":"1996","unstructured":"Capizzi RL: Curative chemotherapy for acute myeloid leukemia: the development of high-dose ara-C from the laboratory to bedside. Invest New Drugs. 1996, 14: 249-256.","journal-title":"Invest New Drugs"},{"key":"1366_CR20","doi-asserted-by":"publisher","first-page":"1657","DOI":"10.2217\/pgs.09.118","volume":"10","author":"JK Lamba","year":"2009","unstructured":"Lamba JK: Genetic factors influencing cytarabine therapy. Pharmacogenomics. 2009, 10: 1657-1674.","journal-title":"Pharmacogenomics"},{"key":"1366_CR21","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1124\/mol.105.021543","volume":"70","author":"ML Clarke","year":"2006","unstructured":"Clarke ML, Damaraju VL, Zhang J, Mowles D, Tackaberry T, Lang T, Smith KM, Young JD, Tomkinson B, Cass CE: The role of human nucleoside transporters in cellular uptake of 4\u2019-thio-beta-D-arabinofuranosylcytosine and beta-D-arabinosylcytosine. Mol Pharmacol. 2006, 70: 303-310.","journal-title":"Mol Pharmacol"},{"issue":"3 Suppl 4","key":"1366_CR22","first-page":"54","volume":"28","author":"RL Capizzi","year":"1991","unstructured":"Capizzi RL, White JC, Powell BL, Perrino F: Effect of dose on the pharmacokinetic and pharmacodynamic effects of cytarabine. Semin Hematol. 1991, 28 (3 Suppl 4): 54-69.","journal-title":"Semin Hematol"},{"key":"1366_CR23","doi-asserted-by":"publisher","first-page":"2349","DOI":"10.1158\/0008-5472.CAN-07-5528","volume":"68","author":"J Cai","year":"2008","unstructured":"Cai J, Damaraju VL, Groulx N, Mowles D, Peng Y, Robins MJ, Cass CE, Gros P: Two distinct molecular mechanisms underlying cytarabine resistance in human leukemic cells. Cancer Res. 2008, 68: 2349-2357.","journal-title":"Cancer Res"},{"key":"1366_CR24","doi-asserted-by":"publisher","first-page":"1388","DOI":"10.1038\/sj.bjc.6602881","volume":"93","author":"I Hubeek","year":"2005","unstructured":"Hubeek I, Stam RW, Peters GJ, Broekhuizen R, Meijerink JPP, van Wering ER, Gibson BES, Creutzig U, Zwaan CM, Cloos J, Kuik DJ, Pieters R, Kaspers GJL: The human equilibrative nucleoside transporter 1 mediates in vitro cytarabine sensitivity in childhood acute myeloid leukaemia. Br J Cancer. 2005, 93: 1388-1394.","journal-title":"Br J Cancer"},{"key":"1366_CR25","doi-asserted-by":"publisher","first-page":"569","DOI":"10.2741\/3944","volume":"17","author":"J Tang","year":"2012","unstructured":"Tang J, Xie X, Zhang X, Qiao X, Jiang S, Shi W, Shao Y, Zhou X: Long term cultured HL-60 cells are intrinsically resistant to Ara-C through high CDA activity. Front Biosci (Landmark Ed). 2012, 17: 569-574.","journal-title":"Front Biosci (Landmark Ed)"},{"key":"1366_CR26","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1007\/BF00686248","volume":"29","author":"LM DeAngelis","year":"1992","unstructured":"DeAngelis LM, Kreis W, Chan K, Dantis E, Akerman S: Pharmacokinetics of ara-C and ara-U in plasma and CSF after high-dose administration of cytosine arabinoside. Cancer Chemother Pharmacol. 1992, 29: 173-177.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"3","key":"1366_CR27","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1182\/blood-2008-02-140038","volume":"113","author":"T Qin","year":"2009","unstructured":"Qin T, Jelinek J, Si J, Shu J, Issa JP: Mechanisms of resistance to 5-aza-2'-deoxycytidine in human cancer cell lines. Blood. 2009, 113 (3): 659-667.","journal-title":"Blood"},{"key":"1366_CR28","doi-asserted-by":"publisher","first-page":"6522","DOI":"10.1038\/onc.2008.316","volume":"27","author":"B Ewald","year":"2008","unstructured":"Ewald B, Sampath D, Plunkett W: Nucleoside analogs: molecular mechanisms signaling cell death. Oncogene. 2008, 27: 6522-6537.","journal-title":"Oncogene"},{"key":"1366_CR29","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1038\/sj.leu.2402114","volume":"15","author":"CM Galmarini","year":"2001","unstructured":"Galmarini CM, Mackey JR, Dumontet C: Nucleoside analogues: mechanisms of drug resistance and reversal strategies. Leukemia. 2001, 15: 875-890.","journal-title":"Leukemia"},{"key":"1366_CR30","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.bcmd.2011.09.007","volume":"48","author":"C Visco","year":"2012","unstructured":"Visco C, Castegnaro S, Chieregato K, Bernardi M, Albiero E, Zanon C, Madeo D, Rodeghiero F: The cytotoxic effects of bendamustine in combination with cytarabine in mantle cell lymphoma cell lines. Blood Cells Mol Dis. 2012, 48: 68-75.","journal-title":"Blood Cells Mol Dis"},{"key":"1366_CR31","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1371\/journal.pone.0090675","volume":"9","author":"N Hiraoka","year":"2014","unstructured":"Hiraoka N, Kikuchi J, Yamauchi T, Koyama D, Wada T, Uesawa M, Akutsu M, Mori S, Nakamura Y, Ueda T, Kano Y, Furukawa Y: Purine analog-like properties of bendamustine underlie rapid activation of DNA damage response and synergistic effects with pyrimidine analogues in lymphoid malignancies. PLoS One. 2014, 9: 1-14.","journal-title":"PLoS One"},{"key":"1366_CR32","unstructured":"Klanova M, Soukup T, Jaksa R, Molinsky J, Lateckova L, Maswabi BC, Prukova D, Brezinova J, Michalova K, Vockova P, Hernandez-Ilizaliturri F, Kulvait V, Zivny J, Vokurka M, Necas E, Trneny M, Klener P: Mouse models of mantle cell lymphoma, complex changes in gene expression and phenotype of engrafted MCL cells: implications for preclinical research. Lab Invest. in press,"}],"container-title":["Molecular Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1476-4598-13-159.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/1476-4598-13-159\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/1476-4598-13-159.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,2]],"date-time":"2021-09-02T00:56:26Z","timestamp":1630544186000},"score":1,"resource":{"primary":{"URL":"https:\/\/molecular-cancer.biomedcentral.com\/articles\/10.1186\/1476-4598-13-159"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,6,27]]},"references-count":32,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2014,12]]}},"alternative-id":["1366"],"URL":"https:\/\/doi.org\/10.1186\/1476-4598-13-159","relation":{},"ISSN":["1476-4598"],"issn-type":[{"value":"1476-4598","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,6,27]]},"assertion":[{"value":"29 January 2014","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 June 2014","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 June 2014","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"159"}}